Nature Communications (Nov 2020)

Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

  • Fatai S. Oladunni,
  • Jun-Gyu Park,
  • Paula A. Pino,
  • Olga Gonzalez,
  • Anwari Akhter,
  • Anna Allué-Guardia,
  • Angélica Olmo-Fontánez,
  • Shalini Gautam,
  • Andreu Garcia-Vilanova,
  • Chengjin Ye,
  • Kevin Chiem,
  • Colwyn Headley,
  • Varun Dwivedi,
  • Laura M. Parodi,
  • Kendra J. Alfson,
  • Hilary M. Staples,
  • Alyssa Schami,
  • Juan I. Garcia,
  • Alison Whigham,
  • Roy Neal Platt,
  • Michal Gazi,
  • Jesse Martinez,
  • Colin Chuba,
  • Stephanie Earley,
  • Oscar H. Rodriguez,
  • Stephanie Davis Mdaki,
  • Katrina N. Kavelish,
  • Renee Escalona,
  • Cory R. A. Hallam,
  • Corbett Christie,
  • Jean L. Patterson,
  • Tim J. C. Anderson,
  • Ricardo Carrion,
  • Edward J. Dick,
  • Shannan Hall-Ursone,
  • Larry S. Schlesinger,
  • Xavier Alvarez,
  • Deepak Kaushal,
  • Luis D. Giavedoni,
  • Joanne Turner,
  • Luis Martinez-Sobrido,
  • Jordi B. Torrelles

DOI
https://doi.org/10.1038/s41467-020-19891-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 17

Abstract

Read online

Here, the authors characterize tissue-level SARS-CoV-2 infection and pathogenesis in transgenic mice expressing human angiotensin converting enzyme 2 (hACE2) by the human cytokeratin 18 promoter (K18-hACE2) and show that infection induces lethality, making the K18-hACE2 model suitable for vaccine and therapeutic evaluation.